The DOI matches its Crossref record; 148 of the 151 references it cites were found in a registry or an index.
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
Abstract
Mental health problems frequently occur in chronic infection with the hepatitis C virus (HCV) and during antiviral treatment with pegylated interferon-alpha (PegIFNα) and ribavirin. Depression is one of the most important complications during antiviral treatment of chronic hepatitis C infection. However, an increased prevalence of depression, fatigue, and cognitive disturbances has also been reported in untreated HCV-positive patients. Patients with psychiatric disorders or drug addiction also have an increased risk of HCV infection. Furthermore, because of possible drug-drug interactions, new antivirals administered together with PegIFNα and ribavirin may complicate psychiatric side effect management, even if no specific psychiatric adverse events are known so far for these new drugs. The European liver patient's organization (ELPA) organised a European expert conference to review the literature and develop expert recommendations for the management of mental health problems in HCV infected patients. This paper results from the output of the 2011 EASL meeting and subsequent dialogue with patient groups and relevant experts in Europe. It summarises the current knowledge of HCV infection and the brain; prevalence, course, and neurobiology of IFN-α associated psychiatric side effects; possible risk factors for IFN-α associated depression and suicide attempts; psychiatric management of HCV infected patients before and during antiviral treatment; prevention of IFN- α associated psychiatric side effects; and psychiatric aspects of the new antivirals. The summarised current knowledge about mental health changes before and during antiviral treatment should improve interdisciplinary management of HCV infected patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Historical data have shown that interferon (INF)based antiviral therapy for patients with HCV is frequently associated with treatment-induced DEP and ANX.[22]”
From Prevalence of depression and anxiety symptoms by liver disease etiology (2023) · cites this paper as [22]
In the citing paper
“Schaefer and colleagues reported the prevalence of DEP during INF treatment to be 30%-70% based on 10 studies, though prevalence rates varied by type of screening instrument.”
From Prevalence of depression and anxiety symptoms by liver disease etiology (2023) · cites this paper as [22]
In the citing paper
“For example, it was estimated that MDD developed in 15%-45% of patients treated with INF, [22] as assessed by diagnostic interview.”
From Prevalence of depression and anxiety symptoms by liver disease etiology (2023) · cites this paper as [22]
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C. I., Marinos, G., Gonçales, F. L., Häussinger, D., Moisés Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,386
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M. L., Reindollar, R., Goodman, Z. D., Koury, K. J., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,027
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,457
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2008) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,986
Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Moisés Diago, M., Marcellin, P., Ramadori, G. P., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,835
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Poordad, F. F., McCone, J., Bacon, B. R., Bruno, S., Manns, M. P., Sulkowski, M., Jacobson, I. M., Reddy, K. R., Goodman, Z. D., Boparai, N., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010494 · Cited by 2,512
Peginterferon Alfa-2a in Patients with Chronic Hepatitis C
Zeuzem, S., Feinman, S. V., Rasenack, J. W. F., Heathcote, E. J., Lai, M., Gane, E. J., O’Grady, J., Reichen, J., Moisés Diago, M., Lin, A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012073432301 · Cited by 1,218
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Self-citationParoxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
1 (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.023 · Cited by 1,080
Flagged first, then by citations
3 of the 151 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Forton, 2008, Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study, J Hepatol, 49, 316, 10.1016/j.jhep.2008.03.022 · DOI
- Schaefer, 2008, Clinical management of interferon-alfa-associated psychiatric side effects during hepatitis C treatment, Hot Top Viral Hepat, 9, 11
Cited by
Sorted by citations
Peck, M., Craxı̀, A., Fried, M., & Zeuzem, S. (2013) · Cited by 1,080
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 872
Extrahepatic Morbidity and Mortality of Chronic Hepatitis C
Negro, F., Forton, D. M., Craxı̀, A., Sulkowski, M., Feld, J. J., & Manns, M. P. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.035 · Cited by 374
Self-citationRoncero, C., Buch-Vicente, B., Martín-Sánchez, Á. M., Álvarez-Navares, A. I., Andrés-Olivera, P., Gamonal-Limcaoco, S., Lozano-López, M. T., Aguilar, L., Sánchez-Casado, F., & García-Ullán, L. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.06.005 · Cited by 230
Su, K.-P., Lai, H.-C., Yang, H.-T., Su, W.-P., Peng, C.-Y., Chang, J. P.-C., Chang, H.-C., & Pariante, C. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.01.008 · Cited by 205
Self-citation
Metadata
- Authors
- Schaefer, M., Capuron, L., Friebe, A., Diez-Quevedo, C., Robaeys, G., Neri, S., Foster, G. R., Kautz, A., Forton, D., & Pariante, C. M.
- Affiliations
- Kliniken Essen-Mitte (DE)
- Université de Bordeaux (FR)
- Ruhr University Bochum (DE)
- Ziekenhuis Oost-Limburg (BE)
- University of Catania (IT)
- Queen Mary University of London (GB)
- University of London (GB)
- King's College London (GB)
- Corresponding author
- Schaefer, Martin
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 57
- Issue
- 6
- Pages
- 1379-1390
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2153538902
- Cited by
- 225
- References
- 151
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 9 · 2023: 6 · 2022: 11 · 2021: 16 · 2020: 16 · 2019: 13 · 2018: 20 · 2017: 22 · 2016: 26 · 2015: 20 · 2014: 26 · 2013: 24 · 2012: 2
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- European Association for the Study of the Liver
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Social Sciences › Psychology › Clinical Psychology › COVID-19 and Mental Health
- Keywords
- hepatitis C, chronic hepatitis C, depression, psychiatric adverse effects, pegylated interferon-alpha, ribavirin, antiviral therapy, mental health, fatigue, cognitive disorders, drug addiction, suicide risk, drug-drug interactions, psychiatric management
- MeSH terms
- Antiviral Agents, Depression, Drug Interactions, Hepatitis C, Humans, Mental Health, Risk Factors, Suicide, Attempted, Interferon-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
